0.0015%他氟前列素与0.005%拉坦前列素治疗原发性开角型青光眼和高眼压症的疗效及安全性：一项Meta分析
Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis.
作者信息
Yang Xi-Ting, Zhao Lin, Wang Li-Jun, Zhang Yi, Liao Ding-Ying, Wang Jian-Ming
机构信息
Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.
出版信息
Int J Ophthalmol. 2020 Mar 18;13(3):474-480. doi: 10.18240/ijo.2020.03.16. eCollection 2020.
AIM
To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of tafluprost 0.0015% eye drops [benzalkonium chloride (BAK) 0.1 mg/mL] compared with that of latanoprost 0.005% eye drops (BAK 0.2 mg/mL) for primary open angle glaucoma (POAG) and ocular hypertension (OHT).
METHODS
All the randomized controlled trials (RCTs) about treating POAG and OHT comparing tafluprost and latanoprost were collected by searching PubMed, Embase, Cochrane Library, CNKI and VIP. The outcomes of interest to evaluate the clinical efficacy and adverse effects included IOP and patient-related drop discomfort.
RESULTS
Five RCTs involving 888 glaucoma patients were included. The results showed that, 1) at the end of the study, no statistically significant differences were observed in IOP reduction [standard mean difference (SMD) =0.48, 95%CI 0.07 to 0.88, =0.085] between tafluprost and latanoprost; 2) No statistically significant differences were observed in adverse events of foreign-body sensation [relative risk (RR) =0.62, 95%CI 0.26 to 1.46, =0.269], eye irritation (RR=1.16, 95%CI 0.49 to 2.75, =0.744), eye pain (RR=2.000, 95%CI 0.949 to 4.216, =0.07), iris hyper-pigmentation (RR=0.741, 95%CI 0.235 to 2.334, =0.61), dry eye (RR=1.154, 95%CI 0.409 to 3.256, =0.79) and eye pruritus (RR=1.600, 95%CI 0.536 to 4.774, =0.4) between tafluprost and latanoprost. However, tafluprost showed more reported incidence of conjunctival hyperaemia than latanoprost (RR=2.11, 95%CI 1.24 to 3.59, =0.006).
CONCLUSION
Tafluprost 0.0015% eye drops (BAK 0.1 mg/mL) and latanoprost 0.005% eye drops (BAK 0.2 mg/mL) are comparable in lowering IOP for open angle glaucoma (OAG) and OHT. It does not differ in the incidence of foreign-body sensation, eye irritation, eye pain, iris hyper-pigmentation, dry eye and eye pruritus, but tafluprost shows less ocular tolerability because of more incidence of conjunctival hyperaemia.
目的
评估0.0015%他氟前列素滴眼液（含0.1 mg/mL苯扎氯铵）与0.005%拉坦前列素滴眼液（含0.2 mg/mL苯扎氯铵）降低原发性开角型青光眼（POAG）和高眼压症（OHT）患者眼压的疗效和安全性。
方法
通过检索PubMed、Embase、Cochrane图书馆、中国知网和维普资讯，收集所有比较他氟前列素和拉坦前列素治疗POAG和OHT的随机对照试验（RCT）。评估临床疗效和不良反应的相关指标包括眼压和患者相关的滴眼不适。
结果
纳入了5项涉及888例青光眼患者的RCT。结果显示，1）研究结束时，他氟前列素和拉坦前列素在降低眼压方面无统计学显著差异[标准均差（SMD）=0.48，95%可信区间为0.07至0.88，P=0.085]；2）在异物感[相对危险度（RR）=0.62，95%可信区间为0.26至1.46，P=0.269]、眼刺激（RR=1.16，95%可信区间为0.49至2.75，P=0.744）、眼痛（RR=2.000，95%可信区间为0.949至4.216，P=0.07）、虹膜色素沉着（RR=0.741，95%可信区间为0.235至2.334，P=0.61）、干眼（RR=1.154，95%可信区间为0.409至3.256，P=0.79）和眼痒（RR=1.600，95%可信区间为0.536至4.774，P=0.4）等不良事件方面，他氟前列素和拉坦前列素之间无统计学显著差异。然而，他氟前列素报告的结膜充血发生率高于拉坦前列素（RR=2.11，95%可信区间为1.24至3.59，P=0.006）。
结论
0.0015%他氟前列素滴眼液（含0.1 mg/mL苯扎氯铵）和0.005%拉坦前列素滴眼液（含0.2 mg/mL苯扎氯铵）在降低开角型青光眼（OAG）和OHT眼压方面具有可比性。在异物感、眼刺激、眼痛、虹膜色素沉着、干眼和眼痒的发生率方面无差异，但他氟前列素因结膜充血发生率较高而眼部耐受性较差。
Zotero 插件